PE20070216A1 - Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion - Google Patents
Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacionInfo
- Publication number
- PE20070216A1 PE20070216A1 PE2006000890A PE2006000890A PE20070216A1 PE 20070216 A1 PE20070216 A1 PE 20070216A1 PE 2006000890 A PE2006000890 A PE 2006000890A PE 2006000890 A PE2006000890 A PE 2006000890A PE 20070216 A1 PE20070216 A1 PE 20070216A1
- Authority
- PE
- Peru
- Prior art keywords
- weight
- preparation
- pharmaceutical compositions
- compositions including
- levetiracetam
- Prior art date
Links
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 title abstract 2
- 229960004002 levetiracetam Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 239000008119 colloidal silica Substances 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 abstract 1
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA DE ADMINISTRACION ORAL QUE COMPRENDE: A) LEVETIRACETAM; B) 2-9% EN PESO DE DESINTEGRANTE TAL COMO CROSCARAMELOSA SODICA; C) 0-3% EN PESO DE AGENTE DESLIZANTE TAL COMO SILICE COLOIDAL ANHIDRA; D) 0,5-6% EN PESO DE AGLUTINANTE TAL COMO POLIETILENGLICOL 6000; E) 0-1% EN PESO DE LUBRICANTE TAL COMO ESTEARATO DE MAGNESIO. TAMBIEN COMPRENDE UN AGENTE DE RECUBRIMIENTO QUE COMPRENDE POLI (ALCOHOL VINILICO). REFERIDA TAMBIEN A UN PROCEDIMIENTO DE PREPARACION.DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE EPILEPSIA, DISCINASIA, MIGRANA, TRASTORNOS BIPOLARES, DOLOR CRONICO, ENTRE OTROS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05016189 | 2005-07-26 | ||
| EP05016945 | 2005-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070216A1 true PE20070216A1 (es) | 2007-03-27 |
Family
ID=36888840
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2010000095A PE20100265A1 (es) | 2005-07-26 | 2006-07-24 | Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion |
| PE2006000890A PE20070216A1 (es) | 2005-07-26 | 2006-07-24 | Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2010000095A PE20100265A1 (es) | 2005-07-26 | 2006-07-24 | Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8802142B2 (es) |
| EP (1) | EP1909764B1 (es) |
| JP (2) | JP5183470B2 (es) |
| KR (1) | KR20080030546A (es) |
| CN (1) | CN101068534B (es) |
| AR (1) | AR054581A1 (es) |
| AU (1) | AU2006274263B2 (es) |
| BR (1) | BRPI0606121A2 (es) |
| CA (1) | CA2581831C (es) |
| CY (1) | CY1115825T1 (es) |
| DK (1) | DK1909764T3 (es) |
| EA (1) | EA014961B1 (es) |
| ES (1) | ES2524771T3 (es) |
| HR (1) | HRP20141185T1 (es) |
| IL (1) | IL182375A0 (es) |
| MX (1) | MX2007004294A (es) |
| NO (1) | NO20071667L (es) |
| NZ (1) | NZ554157A (es) |
| PE (2) | PE20100265A1 (es) |
| PL (1) | PL1909764T3 (es) |
| PT (1) | PT1909764E (es) |
| RS (1) | RS53690B1 (es) |
| SI (1) | SI1909764T1 (es) |
| TW (1) | TW200738280A (es) |
| WO (1) | WO2007012439A1 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005325930B2 (en) | 2005-01-27 | 2012-01-19 | Alembic Limited | Extended release formulation of Levetiracetam |
| CN101360493A (zh) * | 2006-01-24 | 2009-02-04 | 特瓦制药工业有限公司 | 左乙拉西坦制剂和制备方法 |
| FR2912056B1 (fr) * | 2007-02-05 | 2009-12-18 | Rd Pharmagal | Composition a liberation prolongee de levetiracetam et procede de preparation |
| JP2010024156A (ja) * | 2008-07-16 | 2010-02-04 | Ucb Pharma Sa | レベチラセタムを含む医薬組成物 |
| DE102008059206A1 (de) * | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
| CN101422442A (zh) * | 2008-12-09 | 2009-05-06 | 沈阳药科大学 | 左乙拉西坦渗透泵控释片及其制备方法 |
| US20100172979A1 (en) * | 2008-12-24 | 2010-07-08 | Zhongshui Yu | Controlled-release formulations |
| US20100159009A1 (en) * | 2008-12-24 | 2010-06-24 | Zhongshui Yu | Controlled-release formulations |
| WO2010094535A1 (en) * | 2009-01-29 | 2010-08-26 | Ucb Pharma, S.A. | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives |
| AU2010265863C1 (en) | 2009-06-26 | 2012-11-01 | Taris Biomedical Llc | Implantable drug delivery devices and methods of making the same |
| CN102038657B (zh) * | 2009-10-10 | 2015-04-15 | 浙江华海药业股份有限公司 | 左乙拉西坦片及其制备方法 |
| EP2552447A4 (en) * | 2010-03-29 | 2013-09-11 | Hetero Research Foundation | STABLE PHARMACEUTICAL COMPOSITION OF IMATINIB |
| TR201011148A1 (tr) | 2010-12-30 | 2012-07-23 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Levetirasetam farmasötik bileşimleri. |
| CN109662961A (zh) * | 2011-02-09 | 2019-04-23 | 约翰斯霍普金斯大学 | 用于改善认知功能的方法和组合物 |
| CN102188420B (zh) * | 2011-03-25 | 2013-04-10 | 华润赛科药业有限责任公司 | 一种左乙拉西坦的药物组合物及其制备方法 |
| CN102895214B (zh) * | 2012-10-25 | 2014-03-26 | 杭州朱养心药业有限公司 | 左乙拉西坦片剂的固体药物组合物 |
| CN102871981B (zh) * | 2012-10-25 | 2013-11-13 | 杭州朱养心药业有限公司 | 包含左乙拉西坦的片剂药物组合物 |
| CN103127175B (zh) * | 2013-02-22 | 2014-01-22 | 张晓光 | 一种抗癫痫药物及其制备方法 |
| HK1216513A1 (zh) | 2013-03-15 | 2016-11-18 | 阿普雷奇亚制药有限责任公司 | 包含左乙拉西坦的快速分散劑型 |
| US9339489B2 (en) | 2013-03-15 | 2016-05-17 | Aprecia Pharmaceuticals Company | Rapid disperse dosage form containing levetiracetam |
| JP6433482B2 (ja) | 2013-03-15 | 2018-12-05 | エージンバイオ， インコーポレイテッド | 認知機能を改善するための方法および組成物 |
| EP2968237A4 (en) | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION |
| US20170035733A1 (en) * | 2013-11-29 | 2017-02-09 | Ucb Pharma Gmbh | Pharmaceutical composition comprising lacosamide and levetiracetam |
| CN104666263B (zh) * | 2015-02-09 | 2017-07-11 | 海南华益泰康药业有限公司 | 一种含有左乙拉西坦的片剂及其制备方法 |
| BR112017025031B1 (pt) | 2015-05-22 | 2023-03-21 | Agenebio, Inc | Composições farmacêuticas de liberação prolongada de levetiracetam |
| JP6630229B2 (ja) * | 2016-05-17 | 2020-01-15 | エルメッド株式会社 | レベチラセタム含有医薬組成物及びその製造方法 |
| JP6422464B2 (ja) * | 2016-05-19 | 2018-11-14 | エルメッド エーザイ株式会社 | レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤 |
| CN107913258A (zh) * | 2016-10-09 | 2018-04-17 | 北京阜康仁生物制药科技有限公司 | 一种左乙拉西坦缓释片及其制备方法 |
| JP6326114B2 (ja) * | 2016-11-01 | 2018-05-16 | エルメッド エーザイ株式会社 | レベチラセタム含有医薬組成物及びその製造方法、並びにレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止方法、及びレベチラセタム含有医薬組成物の崩壊及び溶出の少なくともいずれかの遅延防止剤 |
| JP7264711B2 (ja) * | 2019-04-26 | 2023-04-25 | 東和薬品株式会社 | レベチラセタム含有医薬組成物の製造方法 |
| JP7575217B2 (ja) * | 2019-08-09 | 2024-10-29 | 日本ジェネリック株式会社 | レベチラセタムを含む錠剤 |
| CN117838643A (zh) * | 2023-12-29 | 2024-04-09 | 山东力诺制药有限公司 | 一种吡拉西坦片及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8412357D0 (en) | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
| EP0618983B1 (en) * | 1992-10-09 | 1999-09-01 | VYSIS, Inc. | Insertion elements and amplifiable nucleic acids |
| BE1011045A3 (fr) | 1997-03-14 | 1999-04-06 | Ucb Sa | Compositions pharmaceutiques pour la liberation controlee de substances actives. |
| MXPA02005275A (es) | 1999-12-01 | 2003-02-17 | Ucb Sa | Derivado de pirrolidinacetamida solo en combinacion para el tratamiento de trastornos del sistema nervioso central. |
| US20040092575A1 (en) * | 2001-03-22 | 2004-05-13 | Jacques Peuvot | Use of certain substituted pyrrolidones such as piracetam in the treatment of viral and other diseases |
| WO2003094913A1 (en) * | 2002-05-14 | 2003-11-20 | Ucb, S.A. | Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug |
| WO2004051222A2 (en) | 2002-12-03 | 2004-06-17 | Ucb, S.A. | Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases |
| US20040185097A1 (en) | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
| WO2004069796A2 (en) | 2003-02-03 | 2004-08-19 | Teva Pharmaceutical Industries Ltd. | Process for producing levetiracetam |
| EP2601953A1 (en) | 2003-05-23 | 2013-06-12 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and mood stabilizers for treating mood disorders |
| AU2005325930B2 (en) | 2005-01-27 | 2012-01-19 | Alembic Limited | Extended release formulation of Levetiracetam |
-
2006
- 2006-07-24 PL PL06776372T patent/PL1909764T3/pl unknown
- 2006-07-24 EP EP06776372.2A patent/EP1909764B1/en not_active Revoked
- 2006-07-24 WO PCT/EP2006/007260 patent/WO2007012439A1/en not_active Ceased
- 2006-07-24 PT PT67763722T patent/PT1909764E/pt unknown
- 2006-07-24 EA EA200700566A patent/EA014961B1/ru not_active IP Right Cessation
- 2006-07-24 DK DK06776372.2T patent/DK1909764T3/da active
- 2006-07-24 CA CA2581831A patent/CA2581831C/en not_active Expired - Fee Related
- 2006-07-24 MX MX2007004294A patent/MX2007004294A/es active IP Right Grant
- 2006-07-24 RS RS20140675A patent/RS53690B1/sr unknown
- 2006-07-24 CN CN2006800012799A patent/CN101068534B/zh active Active
- 2006-07-24 PE PE2010000095A patent/PE20100265A1/es not_active Application Discontinuation
- 2006-07-24 AU AU2006274263A patent/AU2006274263B2/en not_active Ceased
- 2006-07-24 JP JP2008523207A patent/JP5183470B2/ja active Active
- 2006-07-24 KR KR1020077007855A patent/KR20080030546A/ko not_active Ceased
- 2006-07-24 TW TW095126931A patent/TW200738280A/zh unknown
- 2006-07-24 PE PE2006000890A patent/PE20070216A1/es not_active Application Discontinuation
- 2006-07-24 ES ES06776372.2T patent/ES2524771T3/es active Active
- 2006-07-24 HR HRP20141185TT patent/HRP20141185T1/hr unknown
- 2006-07-24 NZ NZ554157A patent/NZ554157A/en not_active IP Right Cessation
- 2006-07-24 BR BRPI0606121-4A patent/BRPI0606121A2/pt not_active Application Discontinuation
- 2006-07-24 SI SI200631863T patent/SI1909764T1/sl unknown
- 2006-07-24 US US11/910,167 patent/US8802142B2/en active Active
- 2006-07-25 AR ARP060103193A patent/AR054581A1/es not_active Application Discontinuation
-
2007
- 2007-03-29 NO NO20071667A patent/NO20071667L/no not_active Application Discontinuation
- 2007-04-01 IL IL182375A patent/IL182375A0/en unknown
-
2012
- 2012-10-12 JP JP2012226516A patent/JP2013018786A/ja active Pending
-
2014
- 2014-12-10 CY CY20141101026T patent/CY1115825T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20070216A1 (es) | Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion | |
| BRPI0514474A (pt) | multiparticulados | |
| MY144992A (en) | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives. | |
| WO2009043987A9 (fr) | Compositions antibiotiques a base d'huiles essentielles - prophylaxie et traitement d'infections nosocomiales | |
| ATE355065T1 (de) | Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika | |
| BRPI0517481A (pt) | método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica | |
| NO20090321L (no) | Anvendelse av substituerte 2-aminotyetraliner for produksjon av et medikament for forhindringen, lettingen og/eller behandlingen av diverse typer smerte | |
| MY143795A (en) | Tetrahydropyridoindole derivatives | |
| BRPI1007379B8 (pt) | composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli | |
| UY31080A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis | |
| EA201200968A1 (ru) | Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин | |
| NZ602538A (en) | Thermogelling anaesthetic compositions | |
| CL2011000144A1 (es) | Compuestos derivados de benzo (1,4) dioxin-2-ilmetil-sulfamida; composiciones farmaceuticas que los contienen; proceso para prepararlos y uso en el tratamiento de la ansiedad, epilepsia, dolor, abuso de sustancias, trastornos relacionados, entre otros. | |
| BRPI0508579A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| MY144897A (en) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
| ZA202308600B (en) | Methods and pharmaceutical composition for treating diseases | |
| TW200716522A (en) | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | |
| BRPI0512357A (pt) | composições compreendendo estrÈncio e vitamina d e usos destas | |
| EA201070806A1 (ru) | Состав медленного высвобождения на основе ассоциации гликогена и альгината | |
| IL172892A0 (en) | Indol-4-sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators | |
| BRPI0506493A (pt) | combinações terapêuticas | |
| AR064185A1 (es) | Composiciones y metodos para tratar las convulsiones | |
| BRPI0407529A (pt) | uso de r-10-hidróxi-10,11-dihidro-carbamazepina em dor neuropática | |
| FR2887150B1 (fr) | Composition pharmaceutique comprenant un elastomere organopolysiloxane et un principe actif solubilise | |
| BR0210063A (pt) | Composição estável e uso da mesma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |